PathoGene | GenomeWeb

PathoGene

NEW YORK (GenomeWeb) — The Translational Genomics Research Institute and Northern Arizona University have been jointly awarded a US patent for an allele-specific, real-time PCR-based assay to detect H1N1 pandemic flu and resistance to antiviral treatments.

DxNA, a privately owned St. George, Utah-based molecular diagnostics firm, will acquire privately held Flagstaff, Ariz.-based Pathogene for an undisclosed amount under an agreement inked by the companies this week.

NEW YORK (GenomeWeb News) – Molecular diagnostics shop DxNA has signed a letter of intent to acquire PCR-based assay development company PathoGene, the companies said this week.

DxNA has acquired exclusive rights to run PathoGene's multiplexed Staphylococcus MRSA+ assay on DxNA's real-time PCR-based GeneStat platform, the companies said this week.

The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.

The company is developing and validating assays for difficult-to-treat and drug-resistant infectious diseases based primarily on targets, biomarkers, and PCR primers developed at the Translational Genomics Research Institute and Northern Arizona University.

The firm, which was founded in August 2008 and is based in Flagstaff, Ariz., develops and validates assays that for the identification of infectious diseases.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.